呼吸器疾患検査の世界市場：2024-2031年

世界の呼吸器疾患検査市場は、予測期間中（2024-2031年）にCAGR 6.3%でかなりの成長が見込まれます。市場拡大を促進する主な要因は、大気汚染レベルの上昇による呼吸器疾患の有病率の漸増です。慢性閉塞性肺疾患（COPD）などの肺疾患やその他の呼吸器疾患を引き起こす大気汚染や危険な化学物質の放出が世界的に増加していることが成長を促しています。これらの検査は早期発見ツールとして利用されるため、結核や院内感染などの疾病の発生も全体的な成長を後押しする追加的な要因となっています。

市場力学

高齢化人口の増加

COPDの有病率の増加は人口の高齢化に起因しており、前述の年齢傾向を効果的に管理するために統合ケアモデルや個別治療計画などの戦術を採用する必要があります。National Centre for Biotechnology Informationによると、2023年12月、25歳以上のCOPD患者数は2020年から2050年にかけて23.0％増加し、2050年には世界で6億人に達すると予測されています。COPDの負担は中低所得地域で大きく増加し、男性の患者数が9.4％増加するのに対し、女性の患者数は47.1％増加すると予測されています。さらに、中低所得地域の患者数は2050年までに高所得地域の患者数を上回ると予測されています。

市場セグメンテーション

世界の呼吸器疾患検査市場を詳細に分析した結果、以下のように区分：

• 製品・サービス別では、機器・デバイス、アッセイ・試薬、サービス・ソフトウェアに細分化されます。
• 検査タイプに基づくと、市場は画像検査、機械的検査、体外診断検査に細分化されます。
• 適応疾患別では、結核、喘息、肺がん、慢性閉塞性肺疾患、その他（間質性肺疾患（ILD）、睡眠時無呼吸症候群）に分類されます。
• エンドユーザーに基づくと、市場は病院・診療所、診断研究所、その他（外来診療センター、政府医療機関）に細分化されます。

結核が最大セグメントと予測

呼吸器疾患検査の世界市場は、適応疾患に基づいて、結核、喘息、肺がん、慢性閉塞性肺疾患、その他に細分化されます。このうち、結核のサブセグメントが市場の最大シェアを占めると予想されます。このセグメントの成長を支える主な要因としては、呼吸器疾患検査技術の研究開発への投資が、診断へのアクセス性、有効性、正確性を高め、結核制圧への世界のイニシアチブを強化することなどが挙げられます。世界保健機関（WHO）によると、2023年には130万人が結核で死亡し、COVID-19に次ぐ感染症キラー第2位となっています。結核は世界で1,060万人が罹患しており、多剤耐性結核は依然として公衆衛生の危機です。2000年以来、7,500万人の命を救う努力が続けられているが、2030年までに結核をなくすという国連の持続可能な開発目標を達成するためには、予防、診断、治療、ケアに毎年130億米ドルが必要です。

市場セグメンテーション：体外診断用医薬品が大きな市場シェアを占める

呼吸器疾患の正確な診断に対するニーズの高まりは、特にウイルスの活動が活発な時期に患者を迅速に診断し、治療するためにアクセスしやすくするマルチプレックス検査によって満たされています。

地域別展望

世界の呼吸器疾患検査市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア太平洋地域）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）を含む地域別にさらに細分化されています。

アジア太平洋地域の医療アクセスとインフラ

呼吸器疾患検査の需要は、医療アクセスとインフラの影響を受け、強固なシステムと適切な施設を持つ国々では検査率が高いです。2023年2月の連邦予算によると、保健省に割り当てられた予算は113億2,200万米ドルで、23年度の109億米ドルを3.4％上回り、保健・家族福祉に109億米ドル、保健調査に38億米ドルが割り当てられています。

北米が主要シェアを占める

米国では肺がんの罹患率が高いため、呼吸器疾患検査、特に肺がんの早期発見と管理のための検査ニーズが高まっています。この需要は、医療システムとこの疾患の影響を受ける個人に大きな負担をかけるものであり、効果的なスクリーニングと治療手段の重要性を浮き彫りにしています。肺がん研究財団によると、2023年には、肺がんは世界的にがん関連死で最も多い数を占め、米国では238,340人が新たに肺がんと診断されると推定されています。肺がんの生涯発症リスクは16人に1人で、男女ともに罹患し、アメリカでは毎年約127,070人の命がこの病気で失われています。

世界の呼吸器疾患検査市場に参入している主要企業には、Abbott Laboratories、Becton, Dickinson, and Co.、Koninklijke Philips N.V.、Merck KGaA、Siemens Healthineers AGなどがあります。

目次

第1章 レポート概要

• 業界の現状分析と成長ポテンシャルの展望
• 調査方法とツール
• 市場内訳
  • セグメント別
  • 地域別

第2章 市場概要と洞察

• 調査範囲
• アナリストの洞察と現在の市場動向
  • 主要業界動向
  • 推奨事項
  • 結論

第3章 競合情勢

• 主要企業分析
• Abbott Laboratories
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Becton, Dickinson, and Co.
  • 会社概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• Koninklijke Philips N.V.
  • 概要
  • 財務分析
  • SWOT分析
  • 最近の動向
• 主要戦略分析

第4章 市場セグメンテーション

• 呼吸器疾患検査の世界市場：製品・サービス別
  • 機器・デバイス
  • アッセイ・試薬
  • サービス・ソフトウェア
• 呼吸器疾患検査の世界市場：検査タイプ別
  • 画像検査
  • 機械的検査
  • 体外診断検査
• 呼吸器疾患検査の世界市場：適応疾患別
  • 結核
  • 喘息
  • 肺がん
  • 慢性閉塞性肺疾患
  • その他（間質性肺疾患（ILD）、睡眠時無呼吸症候群）
• 呼吸器疾患検査の世界市場：エンドユーザー別
  • 病院・診療所
  • 診断研究所
  • その他（外来医療センター、政府医療機関）

第5章 地域別分析

• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • イタリア
  • スペイン
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第6章 企業プロファイル

• Bedfont Scientific Ltd.
• BIOMERIEUX
• Carestream Health, Inc.
• Danaher Corp.
• F. Hoffmann-La Roche Ltd
• Masimo Corp.
• Medtronic Plc
• Merck KGaA
• MGC Diagnostics Corp.
• Nihon Kohden Corp.
• QIAGEN GmbH
• ResMed Corp.
• Siemens Healthineers AG
• Smiths Group plc
• Sysmex Corp.
• Thermo Fisher Scientific Inc.
• Vitalograph

LIST OF TABLES

• 1. Global Respiratory Disease Testing Market Research And Analysis By Product And Service, 2023-2031 ($ Million)
• 2. Global Respiratory Disease Testing By Instruments & Devices Market Research And Analysis By Region, 2023-2031 ($ Million)
• 3. Global Respiratory Disease Testing By Assays & Reagents Market Research And Analysis By Region, 2023-2031 ($ Million)
• 4. Global Respiratory Disease Testing By Services & Software Market Research And Analysis By Region, 2023-2031 ($ Million)
• 5. Global Respiratory Disease Testing Market Research And Analysis By Test Disease Indication 2023-2031 ($ Million)
• 6. Global Imaging Tests Respiratory Disease Testing Market Research And Analysis By Region, 2023-2031 ($ Million)
• 7. Global Mechanical Tests Respiratory Disease Testing Market Research And Analysis By Region, 2023-2031 ($ Million)
• 8. Global In-Vitro Diagnostic Tests Respiratory Disease Testing Market Research And Analysis By Region, 2023-2031 ($ Million)
• 9. Global Respiratory Disease Testing Market Research And Analysis By Disease Indication 2023-2031 ($ Million)
• 10. Global Respiratory Disease Testing For Tuberculosis Market Research And Analysis By Region, 2023-2031 ($ Million)
• 11. Global Respiratory Disease Testing For Asthma Market Research And Analysis By Region, 2023-2031 ($ Million)
• 12. Global Respiratory Disease Testing For Lung Cancer Market Research And Analysis By Region, 2023-2031 ($ Million)
• 13. Global Respiratory Disease Testing For Chronic Obstructive Pulmonary Disease Market Research And Analysis By Region, 2023-2031 ($ Million)
• 14. Global Respiratory Disease Testing For Other Disease Indication Market Research And Analysis By Region, 2023-2031 ($ Million)
• 15. Global Respiratory Disease Testing Market Research And Analysis By End-User, 2023-2031 ($ Million)
• 16. Global Respiratory Disease Testing In Hospitals And Clinics Market Research And Analysis By Region, 2023-2031 ($ Million)
• 17. Global Respiratory Disease Testing In Diagnostics Laboratories Market Research And Analysis By Region, 2023-2031 ($ Million)
• 18. Global Respiratory Disease Testing In Other End-User Market Research And Analysis By Region, 2023-2031 ($ Million)
• 19. Global Respiratory Disease Testing Market Research And Analysis By Region, 2023-2031 ($ Million)
• 20. North American Respiratory Disease Testing Market Research And Analysis By Country, 2023-2031 ($ Million)
• 21. North American Respiratory Disease Testing Market Research And Analysis By Product And Service, 2023-2031 ($ Million)
• 22. North American Respiratory Disease Testing Market Research And Analysis By Test Type, 2023-2031 ($ Million)
• 23. North American Respiratory Disease Testing Market Research And Analysis By Disease Indication 2023-2031 ($ Million)
• 24. North American Respiratory Disease Testing Market Research And Analysis By End-User, 2023-2031 ($ Million)
• 25. European Respiratory Disease Testing Market Research And Analysis By Country, 2023-2031 ($ Million)
• 26. European Respiratory Disease Testing Market Research And Analysis By Product And Service, 2023-2031 ($ Million)
• 27. European Respiratory Disease Testing Market Research And Analysis By Test Type, 2023-2031 ($ Million)
• 28. European Respiratory Disease Testing Market Research And Analysis By Disease Indication 2023-2031 ($ Million)
• 29. European Respiratory Disease Testing Market Research And Analysis By End-User, 2023-2031 ($ Million)
• 30. Asia-Pacific Respiratory Disease Testing Market Research And Analysis By Country, 2023-2031 ($ Million)
• 31. Asia-Pacific Respiratory Disease Testing Market Research And Analysis By Product And Service, 2023-2031 ($ Million)
• 32. Asia-Pacific Respiratory Disease Testing Market Research And Analysis By Test Type, 2023-2031 ($ Million)
• 33. Asia-Pacific Respiratory Disease Testing Market Research And Analysis By Disease Indication 2023-2031 ($ Million)
• 34. Asia-Pacific Respiratory Disease Testing Market Research And Analysis By End-User, 2023-2031 ($ Million)
• 35. Rest Of The World Respiratory Disease Testing Market Research And Analysis By Region, 2023-2031 ($ Million)
• 36. Rest Of The World Respiratory Disease Testing Market Research And Analysis By Product And Service, 2023-2031 ($ Million)
• 37. Rest Of The World Respiratory Disease Testing Market Research And Analysis By Test Type, 2023-2031 ($ Million)
• 38. Rest Of The World Respiratory Disease Testing Market Research And Analysis By Disease Indication 2023-2031 ($ Million)
• 39. Rest Of The World Respiratory Disease Testing Market Research And Analysis By End-User, 2023-2031 ($ Million)

LIST OF FIGURES

• 1. Global Respiratory Disease Testing Market Share By Product And Service, 2023 Vs 2031 (%)
• 2. Global Instruments & Devices Respiratory Disease Testing Market Share By Region, 2023 Vs 2031 (%)
• 3. Global Assays & Reagents Respiratory Disease Testing Market Share By Region, 2023 Vs 2031 (%)
• 4. Global Services & Software Respiratory Disease Testing Market Share By Region, 2023 Vs 2031 (%)
• 5. Global Respiratory Disease Testing Market Share By Test Type 2023 Vs 2031 (%)
• 6. Global Imaging Tests Respiratory Disease Testing Market Share By Region, 2023 Vs 2031 (%)
• 7. Global Mechanical Tests Respiratory Disease Testing Market Share By Region, 2023 Vs 2031 (%)
• 8. Global In-Vitro Diagnostic Tests Respiratory Disease Testing Market Share By Region, 2023 Vs 2031 (%)
• 9. Global Respiratory Disease Testing Market Share By Disease Indication 2023 Vs 2031 (%)
• 10. Global Respiratory Disease Testing For Tuberculosis Market Share By Region, 2023 Vs 2031 (%)
• 11. Global Respiratory Disease Testing For Asthma Market Share By Region, 2023 Vs 2031 (%)
• 12. Global Respiratory Disease Testing For Lung Cancer Market Share By Region, 2023 Vs 2031 (%)
• 13. Global Respiratory Disease Testing For Chronic Obstructive Pulmonary Disease Market Share By Region, 2023 Vs 2031 (%)
• 14. Global Respiratory Disease Testing For Other Disease Indication Market Share By Region, 2023 Vs 2031 (%)
• 15. Global Respiratory Disease Testing Market Share By End-User, 2023 Vs 2031 (%)
• 16. Global Respiratory Disease Testing Hospitals And Clinics Market Share By Region, 2023 Vs 2031 (%)
• 17. Global Respiratory Disease Testing Diagnostics Laboratories Market Share By Region, 2023 Vs 2031 (%)
• 18. Global Respiratory Disease Testing For Other End-User Market Share By Region, 2023 Vs 2031 (%)
• 19. Global Respiratory Disease Testing Market Share By Region, 2023 Vs 2031 (%)
• 20. US Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 21. Canada Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 22. UK Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 23. France Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 24. Germany Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 25. Italy Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 26. Spain Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 27. Rest Of Europe Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 28. India Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 29. China Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 30. Japan Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 31. South Korea Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 32. Rest Of Asia-Pacific Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 33. Latin America Respiratory Disease Testing Market Size, 2023-2031 ($ Million)
• 34. Middle East And Africa Respiratory Disease Testing Market Size, 2023-2031 ($ Million)

Global Respiratory Disease Testing Market Size, Share & Trends Analysis Report by Product and Service (Instruments & Devices, Assays & Reagents, and Services & Software), by Test Type (Imaging Tests, Mechanical Tests, and In-vitro Diagnostic Tests), by Disease Indication (Tuberculosis, Asthma, Lung Cancer, Chronic Obstructive Pulmonary Disease, and Others) and by End Users (Hospitals and Clinics, Diagnostics Laboratories, and Others) Forecast Period (2024-2031)

The global respiratory disease testing market is anticipated to grow at a considerable CAGR of 6.3% during the forecast period (2024-2031). The primary driver propelling the market's expansion is the progressively increasing prevalence of respiratory diseases caused by rising air pollution levels. The growth has been prompted by the increasing rate of air pollution and the release of dangerous chemicals leading to lung ailments, such as chronic obstructive pulmonary disease (COPD), and other respiratory diseases globally. The development of diseases such as tuberculosis and hospital-acquired infections, since these tests are utilized as early detection tools, are additional drivers propelling the overall growth.

Market Dynamics

Increasing Prevalence of Aging Population

The increasing prevalence of COPD is attributed to the aging population, leading to it being necessary to employ tactics such as integrated care models and individualized treatment plans to effectively manage the aforementioned age trend. According to the National Centre for Biotechnology Information, in December 2023, it is projected that the global number of COPD cases among individuals aged 25 years and older will experience a 23.0% increase from 2020 to 2050, resulting in an estimated 600.0 million patients globally by 2050. The burden of COPD is expected to grow significantly in low- and middle-income regions, with the number of cases in women projected to increase by 47.1% compared to a 9.4% increase for men. Additionally, the number of cases in low- and middle-income regions is anticipated to surpass that of high-income regions by 2050.

Technological Advancements

Technological advancements in data analytics and visualization are driving the development of interactive dashboards and detailed reports for respiratory virus monitoring tools. For instance, in January 2024, the Texas Department of State Health Services introduced new data tools to monitor respiratory viruses in the state. The dashboard displays trends in illnesses from influenza, COVID-19, and RSV, including emergency room visits, hospitalizations, and deaths. The weekly report provides in-depth information on these diseases.

Market Segmentation

Our in-depth analysis of the global respiratory disease testing market includes the following segments by product and service, application, disease indication, and end-user:

• Based on product and service, the market is sub-segmented into instruments & devices, assays & reagents, and services & software.
• based on application, the market is sub-segmented into imaging tests, mechanical tests, and in-vitro diagnostic tests.
• Based on disease indication, the market is bifurcated into tuberculosis, asthma, lung cancer, chronic obstructive pulmonary disease, and others (interstitial lung disease (ILD), and sleep apnea).
• Based on end-users, the market is sub-segmented into hospitals and clinics, diagnostics laboratories, and others (ambulatory care centers, and government health agencies).

Tuberculosis is Projected to Emerge as the Largest Segment

Based on the disease indication, the global respiratory disease testing market is sub-segmented into tuberculosis, asthma, lung cancer, chronic obstructive pulmonary disease, and others. Among these, the tuberculosis sub-segment is expected to hold the largest share of the market. The primary factor supporting the segment's growth includes investments in research and development for respiratory illness testing technologies are increasing diagnostic accessibility, efficacy, and accuracy, which enhances global initiatives to control tuberculosis. According to the World Health Organization in 2023, 1.3 million individuals died from TB, making it the second leading infectious killer after COVID-19. TB affects 10.6 million individuals globally, with multidrug-resistant TB remaining a public health crisis. Despite efforts to save 75.0 million lives since 2000, $13.0 billion is needed annually for prevention, diagnosis, treatment, and care to achieve the UN Sustainable Development Goals of ending TB by 2030.

In-vitro Diagnostic Tests Sub-segment to Hold a Considerable Market Share

The increasing need for accurate diagnosis of respiratory diseases is met by multiplex testing, which renders it accessible to diagnose patients rapidly and treat patients, especially during viral periods of high activity. For instance, in July 2022, Hologic launched Panther Fusion SARS-CoV-2/Flu A/B/RSV assay and Novodiag RESP-4 molecular diagnostic test for sale in the European Union. These tests detect and differentiate four prevalent respiratory viruses namely SARS-CoV-2, influenza A, influenza B, and RSV. Both tests are compliant with the European In Vitro Diagnostic Medical Device Directive (IVDD) 98/79/EC and EU 2017/746.

Regional Outlook

The global respiratory disease testing market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Healthcare access and infrastructure In Asia-Pacific Region

The demand for respiratory disease testing is influenced by healthcare access and infrastructure, with countries with robust systems and adequate facilities experiencing higher testing rates. According to the Union Budget, in February 2023, allocated $11.322 billion for the Ministry of Health, 3.4% higher than FY23's $10.9 billion, with $10.9 billion for health and family welfare and $3.8 for Health Research.

North America Holds Major Market Share

The high incidence of lung cancer in the US has led to an increased need for respiratory disease testing, specifically for the early identification and management of the condition. This demand places a significant strain on healthcare systems and individuals influenced by the disease, highlighting the importance of effective screening and treatment measures. According to the Lung Cancer Research Foundation, in 2023, lung cancer accounts for the highest number of cancer-related deaths globally, with an estimated 238,340 new cases expected to be diagnosed in the US in 2023. The lifetime risk of developing lung cancer is 1 in 16, affecting both men and women, and approximately 127,070 lives are lost to the disease each year in America.

The major companies serving the global respiratory disease testing market include Abbott Laboratories, Becton, Dickinson, and Co., Koninklijke Philips N.V., Merck KGaA, and Siemens Healthineers AG, among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers, and acquisitions to stay competitive in the market. for instance, in February 2024, GSK acquired Aiolos Bio, a biopharmaceutical company focusing on treating respiratory and inflammatory conditions. The acquisition includes AIO-001, a long-acting anti-thymic stromal lymphopoietin monoclonal antibody for adult asthma treatment. This could expand GSK's respiratory biologics portfolio to 40.0% of severe asthma patients with low T2 inflammation.

• In December 2023, AstraZeneca acquired Icosavax, the acquisition strengthened AstraZeneca's vaccines & immune therapies late-stage pipeline, including IVX-A12, a potential first-in-class, Phase III-ready, combination protein VLP vaccine targeting both RSV and human metapneumovirus. IVX-A12 has a differentiated profile compared to currently approved RSV vaccines.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. By Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Industry Trends
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Abbott Laboratories
  • 3.2.1. Overview
  • 3.2.2. Financial Analysis
  • 3.2.3. SWOT Analysis
  • 3.2.4. Recent Developments
• 3.3. Becton, Dickinson, and Co.
  • 3.3.1. Overview
  • 3.3.2. Financial Analysis
  • 3.3.3. SWOT Analysis
  • 3.3.4. Recent Developments
• 3.4. Koninklijke Philips N.V.
  • 3.4.1. Overview
  • 3.4.2. Financial Analysis
  • 3.4.3. SWOT Analysis
  • 3.4.4. Recent Developments
• 3.5. Key Strategy Analysis

4. Market Segmentation

• 4.1. Global Respiratory Disease Testing Market by Product and Service
  • 4.1.1. Instruments & Devices
  • 4.1.2. Assays & Reagents
  • 4.1.3. Services & Software
• 4.2. Global Respiratory Disease Testing Market by Test Type
  • 4.2.1. Imaging Tests
  • 4.2.2. Mechanical Tests
  • 4.2.3. In-vitro Diagnostic Tests
• 4.3. Global Respiratory Disease Testing Market by Disease Indication
  • 4.3.1. Tuberculosis
  • 4.3.2. Asthma
  • 4.3.3. Lung Cancer
  • 4.3.4. Chronic Obstructive Pulmonary Disease
  • 4.3.5. Others (Interstitial Lung Disease (ILD), and Sleep Apnea)
• 4.4. Global Respiratory Disease Testing Market by End-user
  • 4.4.1. Hospitals and Clinics
  • 4.4.2. Diagnostics Laboratories
  • 4.4.3. Others (Ambulatory Care Centers, and Government Health Agencies)

5. Regional Analysis

• 5.1. North America
  • 5.1.1. United States
  • 5.1.2. Canada
• 5.2. Europe
  • 5.2.1. UK
  • 5.2.2. Germany
  • 5.2.3. Italy
  • 5.2.4. Spain
  • 5.2.5. France
  • 5.2.6. Rest of Europe
• 5.3. Asia-Pacific
  • 5.3.1. China
  • 5.3.2. India
  • 5.3.3. Japan
  • 5.3.4. South Korea
  • 5.3.5. Rest of Asia-Pacific
• 5.4. Rest of the World
  • 5.4.1. Latin America
  • 5.4.2. Middle East & Africa

6. Company Profiles

• 6.1. Bedfont Scientific Ltd.
• 6.2. BIOMERIEUX
• 6.3. Carestream Health, Inc.
• 6.4. Danaher Corp.
• 6.5. F. Hoffmann-La Roche Ltd
• 6.6. Masimo Corp.
• 6.7. Medtronic Plc
• 6.8. Merck KGaA
• 6.9. MGC Diagnostics Corp.
• 6.10. Nihon Kohden Corp.
• 6.11. QIAGEN GmbH
• 6.12. ResMed Corp.
• 6.13. Siemens Healthineers AG
• 6.14. Smiths Group plc
• 6.15. Sysmex Corp.
• 6.16. Thermo Fisher Scientific Inc.
• 6.17. Vitalograph